|1.||Boguniewicz, Mark: 3 articles (06/2008 - 03/2006)|
|2.||Hebert, Adelaide A: 2 articles (06/2008 - 01/2008)|
|3.||Lucky, Anne W: 2 articles (06/2008 - 01/2008)|
|4.||Abramovits, William: 2 articles (01/2008 - 03/2006)|
|5.||Ou, Liang-Shiou: 1 article (02/2015)|
|6.||Azmi, Soraya: 1 article (02/2015)|
|7.||Tang, Mark B Y: 1 article (02/2015)|
|8.||Parekh, Pankaj R: 1 article (02/2015)|
|9.||Leong, Kin Fon: 1 article (02/2015)|
|10.||Low, Wilson H H: 1 article (02/2015)|
|1.||Atopic Dermatitis (Atopic Eczema)
06/01/2009 - "Two previous randomized, double-blind, vehicle-controlled clinical studies provided evidence that Atopiclair is effective in the treatment of atopic dermatitis. "
06/01/2008 - "MAS063DP cream is effective and safe as monotherapy for the treatment of symptoms of mild to moderate atopic dermatitis in infants and children."
03/01/2006 - "MAS063DP cream was confirmed to be a safe and effective treatment for mild to moderate atopic dermatitis in adults."
02/01/2015 - "Cost-effectiveness study of pediatric atopic dermatitis in Asia: atopiclair vs. regular emollient (AD-ATOP)."
11/01/2008 - "A multicenter, randomized, double-blind, vehicle-controlled clinical study was conducted to evaluate the efficacy and safety of MAS063DP in 60 paediatric patients affected by atopic dermatitis (AD), aged between 2 and 17 years. "
|3.||Contact Dermatitis (Eczema, Contact)
05/01/2009 - "MAS063DP cream has received marketing authorization in the USA and the EU as a medical device for the relief of symptoms of atopic dermatitis (AD) and contact dermatitis. "
03/01/2006 - "MAS063DP cream has received marketing authorization in the US and the European Union for symptom relief of atopic dermatitis (eczema) and contact dermatitis. "
01/01/2008 - "MAS063DP (Atopiclair) is a topical cream approved for symptomatic relief in the treatment of atopic and contact dermatitis. "